Dhingra R C, Amat-Y-Leon F, Wyndham C, Denes P, Wu D, Pouget J M, Rosen K M
Am J Cardiol. 1976 Oct;38(4):429-34. doi: 10.1016/0002-9149(76)90458-6.
Electrophysiologic studies were conducted in 17 patients without apparent sinus node disease before and after intravenous administration of 1 to 2 mg of atropine. Mean values in milliseconds (+/- standard error of the mean) before and after administration of atropine were as follows: sinus cycle length 846 +/- 26.4 versus 647 +/- 20.0 (P less than 0.001); sinus nodal recovery time 1,029 +/- 37 versus 774 +/- 36 (P less than 0.001); mean calculated sinoatrial (S-A) conduction time 103 +/- 5.7 versus 58 +/- 3.9 (P less than 0.001); mean P-A interval 34 +/- 1.5 msec versus 31 +/- 1.5 (P less than 0.05); mean atrial effective and functional refractory periods during sinus rhythm 285 +/- 11.3 versus 238 +/- 7.9 and 331 +/0 11.6 versus 280 +/- 8.6, respectively (P less than 0.001 for both); mean atrial effective and functional refractory periods measured at equivalent driven cycle length 239 +/- 7.7 versus 213 +/- 7.4 and 277 +/- 11.4 versus 245 +/- 9.5, respectively (P less than 0.001 for both). In conclusion, atropine shortened sinus cycle length, sinus nodal recovery time and calculated S-A conduction time. The shortening of atrial refractory periods with atropine implies that vagotonia prolongs atrial refractoriness in man.
对17例无明显窦房结疾病的患者在静脉注射1至2毫克阿托品前后进行了电生理研究。阿托品给药前后以毫秒为单位的平均值(±平均标准误差)如下:窦性周期长度846±26.4对比647±20.0(P<0.001);窦房结恢复时间1029±37对比774±36(P<0.001);平均计算得出的窦房(S-A)传导时间103±5.7对比58±3.9(P<0.001);平均P-A间期34±1.5毫秒对比31±1.5(P<0.05);窦性心律时心房有效不应期和功能不应期的平均值分别为285±11.3对比238±7.9以及331±11.6对比280±8.6(两者均P<0.001);在等效驱动周期长度下测量的心房有效不应期和功能不应期的平均值分别为239±7.7对比213±7.4以及277±11.4对比245±9.5(两者均P<0.001)。总之,阿托品缩短了窦性周期长度、窦房结恢复时间以及计算得出的S-A传导时间。阿托品使心房不应期缩短意味着迷走神经张力增高会延长人类心房的不应期。